Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Page 15 of 15
Jan 9, 2026Former New Mountain Capital executive Matt Holt explores combining five health tech startups into the 'Thoreau' platform, seeking to streamline services across payers, providers, and data. If successful, this ambitious project would rank among the largest private equity-backed ventures in health tech.
Jan 8, 2026The significant funding round by Parabilis Medicines exemplifies renewed investor interest in oncology drug development, amid a broader wave of biotech financing involving several other emerging companies this January.
Jan 8, 2026The funding round led by Parabilis highlights the strong biotech fundraising environment as several companies have attracted significant capital recently. These investments underpin ongoing efforts to develop innovative cancer treatments.
Jan 8, 2026The surge in mergers and acquisitions within obesity and diabetes therapeutics marked a major investment shift in 2025, reflecting increased market confidence in these disease areas despite broader funding challenges.
Jan 8, 2026J.P. Morgan’s report highlights unprecedented dealmaking in obesity and diabetes sectors in 2025. The surge in mergers and acquisitions contrasts with downward trends in other investment forms, signaling strategic consolidation in this therapeutic area.
Jan 6, 2026An announcement from investment firm Catalio highlights its strategic commitment to autoimmune disease innovation through leadership appointment at a newly formed biotech startup dedicated to this area.
Jan 6, 2026As healthcare systems become increasingly strained, emphasis on personalized patient experiences and empathy is growing. Investment and innovation focused on scaling these human-centered approaches may redefine patient satisfaction and competitive positioning.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.